Cumulative incidence and risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B who achieved sustained disappearance of viremia by nucleos(t)ide analog treatment

Publisher： John Wiley & Sons Inc

E-ISSN： 1872-034x|48|3|E240-E251

ISSN： 1386-6346

Source： HEPATOLOGY RESEARCH, Vol.48, Iss.3, 2018-02, pp. : E240-E251

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Utility of Prediction Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues

By  

Oncology, Vol. 90, Iss. 4, 2016-03 ,pp. : 199-208

Karger

Access to resources Recommend Favorite

Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: A population‐based cohort study

By  

CANCER, Vol. 121, Iss. 9, 2015-05 ,pp. : 1446-1455

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: which patients with hepatitis B virus‐related hepatocellular carcinoma should receive nucleos(t)ide analogue therapy?

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 44, Iss. 8, 2016-10 ,pp. : 908-910

John Wiley & Sons Inc

Access to resources Recommend Favorite

Stopping long‐term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg‐negative chronic hepatitis B

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 38, Iss. S1, 2018-02 ,pp. : 90-96

John Wiley & Sons Inc

Access to resources Recommend Favorite

Reduced risk of relapse after long‐term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 9, 2015-05 ,pp. : 867-876

John Wiley & Sons Inc

Access to resources Recommend Favorite